FATE News and Press, Fate Therapeutics Inc. From 12/12/23

2023-12-12 16:51:29 ET Gainers: Innovative International Acquis ( IOAC ) +24% . EF Hutton Acquisition Corporation  ( EFHT ) +5% . Denali Therapeutics  ( DNLI ) +4% . SLM Corporation ( SLM ) +4% . BioCryst Pharmaceuticals ( BC...

2023-11-12 12:10:29 ET Summary Fate Therapeutics stock has fallen 50% and lost 90% of its market cap, validating negative stance on the company. Janssen walked away from a partnership deal with Fate, resulting in a huge loss for shareholders. Fate's current pipeline consists o...

2023-11-09 09:00:27 ET More on Fate Therapeutics Fate Therapeutics: Not Now, Maybe Never? Seeking Alpha’s Quant Rating on Fate Therapeutics For further details see: Fate Therapeutics files $300M mixed securities shelf

2023-11-08 21:12:05 ET Fate Therapeutics, Inc. (FATE) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Scott Wolchko - President & Chief Executive Officer Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Research & ...

2023-11-08 16:02:03 ET Fate Therapeutics press release ( NASDAQ: FATE ): Q3 GAAP EPS of -$0.46 beats by $0.12 . Revenue of $1.94M (-87.0% Y/Y) beats by $1.04M . For further details see: Fate Therapeutics GAAP EPS of -$0.46 beats by $0.12, revenue of $1.94...

Phase 1 Study Open for Enrollment of FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning Chemotherapy IND Application Cleared by FDA for FT825/ONO-8250 CAR T-cell Program for S...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Fate Therapeutics Inc. (FATE) is expected to report $-0.59 for Q3 2023

SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived c...

2023-09-20 11:55:57 ET More on Health Care Sector: Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Health Care Select Sector SPDR ETF declares quarterly distribution of $0.5395 BofA clients were net buyers of U.S. equities for a fifth consecutiv...